Dimerix Obtains US Patent for DMX-652 Extending Protection Through 2043, Advancing Acute Kidney Injury Treatment Pipeline

US Patent Grant Enhances DMX-652 Intellectual Property Portfolio Through Mid-2043

The USPTO has issued a core patent for Dimerix’s DMX-652 compound titled "N-cyanopyrrolidines with activity as USP30 inhibitors" under patent number US 12,679,833. This patent provides composition of matter claims protecting the drug candidate until 11 April 2043, marking a critical milestone by securing comprehensive intellectual property rights in the US market. The extended patent term enhances the asset’s commercial value by granting an exclusivity period for potential market approval and future commercialization.

An additional 677 days of patent term adjustment was granted by the USPTO, extending the original expiration date from 2041 by nearly two years. This extension, resulting from regulatory processing delays, strengthens Dimerix’s ability to protect DMX-652 from generic competition. Furthermore, a divisional patent application has been filed to pursue further claims that may cover specific formulations, uses, or manufacturing processes, potentially expanding the scope of protection.

DMX-652’s Mechanism and Clinical Development in Acute Kidney Injury

DMX-652 acts as a selective inhibitor of USP30, a mitochondrial enzyme responsible for regulating mitophagy—the removal of damaged mitochondria in cells. By inhibiting USP30, DMX-652 aims to improve mitochondrial quality control in injured kidney cells, particularly relevant in acute kidney injury caused by ischemia, toxins, or sepsis. The drug is administered orally once daily in capsule form, facilitating patient compliance.

The US Food and Drug Administration has approved the Phase 2 trial protocol under an existing Investigational New Drug application, allowing Dimerix to advance clinical testing without delays from new IND submissions. Pharmaceutical-grade DMX-652 has been manufactured under current good manufacturing practice (GMP) standards and is ready for Phase 2 initiation. The trial will assess DMX-652’s ability to prevent kidney injury and preserve renal function in patients undergoing cardiac surgery.

Acute Kidney Injury Presents Significant Market Opportunity With No Approved Therapies

Acute kidney injury is a severe condition frequently occurring after cardiac surgery or during sepsis, characterized by rapid kidney function decline and high morbidity and mortality. Approximately 260,000 patients annually in major markets including the US, Germany, France, Italy, Spain, and the UK are affected, highlighting a substantial unmet medical need and potential orphan drug designation eligibility.

No approved treatments currently exist specifically for acute kidney injury, leaving supportive care as the primary management approach. The condition often leads to chronic kidney disease and long-term complications, burdening patients and healthcare systems. Notably, about 25% of patients develop acute kidney injury following on-pump cardiac surgery, underscoring the clinical importance of therapeutic interventions like DMX-652.

Comprehensive Development and Manufacturing Assets Included in DMX-652 Acquisition

Dimerix’s acquisition of DMX-652 encompassed the chemical compound, intellectual property rights, and essential development and manufacturing assets to advance commercialization. This includes composition of matter patent protection, the open IND with the FDA permitting clinical trials, and an FDA-approved Phase 2 protocol, eliminating regulatory delays.

The acquisition also provided pharmaceutical-grade drug product manufactured under GMP standards, along with all manufacturing methodologies, enabling rapid Phase 2 trial commencement without additional development or regulatory hurdles. This reduces technical and commercial risks associated with scaling production if clinical benefits are confirmed.

Dimerix’s Pipeline Also Features Phase 3 Program for Focal Segmental Glomerulosclerosis

In addition to DMX-652, Dimerix is progressing DMX-200, its lead candidate in Phase 3 development for focal segmental glomerulosclerosis (FSGS), a rare and severe kidney disease marked by scarring of the kidney’s filtering units. FSGS affects over 40,000 patients in the US, including adults and children, representing a significant unmet medical need.

DMX-200 is a chemokine receptor antagonist targeting CCR2, involved in inflammatory cell recruitment contributing to glomerular injury. It is administered alongside angiotensin II type I receptor blockers, the standard care for hypertension and kidney disease. Patents protect DMX-200 until 2032, with additional applications potentially extending protection to 2042. The drug has received Orphan Drug Designation in the US, Europe, UK, and Japan, offering regulatory incentives.

Unmet Needs in FSGS Highlight Long-Term Commercial Potential

FSGS lacks approved therapies in the US, with treatment relying on non-specific immunosuppressants and supportive care. Disease progression is rapid, with many patients reaching end-stage renal disease within five years. Recurrence after kidney transplantation occurs in up to 60% of cases, emphasizing the need for systemic disease-modifying treatments.

DMX-200’s targeting of CCR2 aligns with the inflammatory mechanisms driving FSGS progression, offering a promising therapeutic approach. The combination of high unmet need, defined patient population, and disease-modifying potential positions DMX-200 as a compelling candidate in late-stage development.

Global Commercial Strategy Supported by Five International Partnerships

Dimerix has established five commercial partnerships across multiple regions and indications to support global development and market access for its kidney disease therapies, including DMX-200 and DMX-652. These collaborations distribute development costs and responsibilities, enabling Dimerix to focus on clinical and regulatory progress while partners manage commercialization activities.

This strategy facilitates worldwide patient access, incorporates partner insights into development planning, and strengthens Dimerix’s negotiating position with regulators and potential acquirers by demonstrating market demand and industry commitment.

Divisional Patent Application Aims to Expand DMX-652 Intellectual Property Protection

Alongside the core patent, Dimerix has filed a divisional patent application with the USPTO to pursue additional claims on DMX-652. Divisional applications allow protection of different inventive aspects disclosed in the original application but not covered in the granted patent, such as alternative formulations, uses, dosing regimens, or manufacturing methods.

This approach can extend patent exclusivity and create additional barriers to competitors, even if they develop chemically distinct compounds with similar effects. Filing divisional patents is a common industry practice to maximize IP value and demonstrates Dimerix’s commitment to a robust patent estate.

Regulatory Pathway and Upcoming Clinical Milestones for DMX-652

Dimerix is set to commence Phase 2 clinical trials of DMX-652 in acute kidney injury related to cardiac surgery, marking a key development milestone. FDA approval of the Phase 2 protocol under the existing IND enables immediate patient recruitment and study initiation without regulatory delays.

Beyond cardiac surgery-associated acute kidney injury, DMX-652 has potential applications in other conditions involving mitochondrial dysfunction and impaired mitophagy, such as sepsis-induced or toxin-related acute kidney injury. The oral once-daily formulation and mechanism targeting mitochondrial quality control suggest broad therapeutic applicability. Positive Phase 2 results could support expanded development into multiple indications.